Mass Cytometry Analysis Reveals Hyperactive NF Kappa B Signaling in Myelofibrosis and Secondary Acute Myeloid Leukemia

Myeloproliferative neoplasms (MPNs) feature a malignant clone containing the JAK2 V617F mutation, or another mutation causing dysregulated JAK2 kinase activity. The multiple disease phenotypes of MPNs, and their tendency to transform phenotypically, suggest pathophysiologic heterogeneities beyond a common phenomenon of JAK2 hyperactivation. JAK2 has the potential to activate multiple other signaling molecules, either directly through downstream effectors, or indirectly through induction of target gene expression. We have interrogated myeloproliferative signaling in myelofibrosis (MF) and secondary acute myeloid leukemia (sAML) patient samples using mass cytometry, which allows the quantitative measurement of multiple signaling molecules simultaneously at the single-cell level, in cell populations representing a nearly complete spectrum of hematopoiesis. MF and sAML malignant cells demonstrated a high prevalence of hyperactivation of the JAK-STAT, MAP kinase, PI3 kinase and NFκB signaling pathways. Constitutive NFκB signaling was evident across MF and sAML patients. A supporting gene set enrichment analysis (GSEA) of MF showed many NFκB target genes to be expressed above normal levels in MF patient CD34+ cells. NFκB inhibition suppressed colony formation from MF CD34+ cells. This study indicates that NFκB signaling contributes to human myeloproliferative disease and is abnormally activated in MF and sAML.

• Publication year

  2016

• Venue

  Leukemia

• Publication date

  2016-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/leu.2016.377PMID 28008177PMCID 5540814
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Somatic mutations of calreticulin in myeloproliferative neoplasms

  2017cited by this paper
• Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.

  2016cited by this paper
• Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm

  2015cited by this paper
• Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy.

  2015cited by this paper
• Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis.

  2015cited by this paper
• Clinical and molecular genetic characterization of myelofibrosis

  2015cited by this paper
• miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis.

  2014cited by this paper
• Conditional density-based analysis of T cell signaling in single-cell data

  2014cited by this paper
• Transient partial permeabilization with saponin enables cellular barcoding prior to surface marker staining

  2014cited by this paper
• Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.

  2014cited by this paper
• Genetics of Myeloproliferative Neoplasms

  2014cited by this paper
• Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AML

  2014cited by this paper
• Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity.

  2014cited by this paper
• Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.

  2013cited by this paper
• The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-κB and is aberrantly regulated in acute myeloid leukemia

  2013cited by this paper
• Epigenetic roles of MLL oncoproteins are dependent on NF-κB.

  2013cited by this paper
• Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

  2013cited by this paper
• Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.

  2013cited by this paper
• Somatic mutations of calreticulin in myeloproliferative neoplasms.

  2013cited by this paper
• Genetic aberrations of signaling pathways in lymphomagenesis: revelations from next generation sequencing studies.

  2013cited by this paper
• viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia

  2013cited by this paper
• MLL1, a H3K4 methyltransferase, regulates the TNF&agr;-stimulated activation of genes downstream of NF-&kgr;B

  2012cited by this paper
• Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators

  2012cited by this paper
• Clonal Evolution Revealed by Whole Genome Sequencing in a Case of Primary Myelofibrosis Transformed to Secondary Acute Myeloid Leukemia

  2012cited by this paper
• The origin and evolution of mutations in acute myeloid leukemia.

  2012cited by this paper
• A platinum‐based covalent viability reagent for single‐cell mass cytometry

  2012cited by this paper
• Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.

  2011cited by this paper
• TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.

  2011cited by this paper
• Recurring mutations in myeloproliferative neoplasms alter epigenetic regulation of gene expression.

  2011cited by this paper
• Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum

  2011cited by this paper
• Single-cell phospho-specific flow cytometric analysis demonstrates biochemical and functional heterogeneity in human hematopoietic stem and progenitor compartments.

  2011cited by this paper
• Extracting a Cellular Hierarchy from High-dimensional Cytometry Data with SPADE

  2011cited by this paper
• Circulating IL-2R, IL-8, IL-15 and CXCL10 Levels Are Independently Prognostic In Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study

  2010cited by this paper
• Inaugural Article: B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression

  2010cited by this paper
• Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling.

  2010cited by this paper
• Pim-1 controls NF-κB signalling by stabilizing RelA/p65

  2010cited by this paper
• Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.

  2010cited by this paper
• DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.

  2010cited by this paper
• Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.

  2010cited by this paper
• ATM mediates constitutive NF-κB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia

  2009cited by this paper
• Flt3 receptor inhibition reduces constitutive NFκB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia

  2008cited by this paper
• Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates.

  2008cited by this paper
• Erratum to: Flt3 receptor inhibition reduces constitutive NFκB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia

  2008cited by this paper
• Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53.

  2007cited by this paper
• Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis.

  2007cited by this paper
• Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood.

  2007cited by this paper
• Molecular Profiling of CD34+ Cells in Idiopathic Myelofibrosis Identifies a Set of Disease‐Associated Genes and Reveals the Clinical Significance of Wilms' Tumor Gene 1 (WT1)

  2007cited by this paper
• JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.

  2007cited by this paper
• Beyond IκBs: alternative regulation of NF‐KB activity

  2007cited by this paper
• Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

  2006cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

  2005cited by this paper
• From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

  2005cited by this paper
• X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis.

  2005cited by this paper
• Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

  2005cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

  2005cited by this paper
• Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

  2005cited by this paper
• A gain-of-function mutation of JAK2 in myeloproliferative disorders.

  2005cited by this paper
• Single cell profiling of potentiated phospho-protein networks in cancer cells.

  2004cited by this paper
• Frederick R. Rickles, MD, FACP, Appointed Executive Director of the Federation of American Societies for Experimental Biology

  2004cited by this paper
• Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells.

  2001cited by this paper

• A First-in-Class JAK/ROCK Inhibitor, Rovadicitinib in Patients with Myelofibrosis who were Refractory or Relapsed or Intolerant to Ruxolitinib: A Single-Arm, Multicenter, Open-Label, Phase Ib Study.

  2025cites this paper
• Chronic Inflammation in Primary Myelofibrosis: In-Depth Insights Into Pathogenesis and Promising Anti-Inflammatory Therapeutic Strategies

  2025cites this paper
• Inflammatory mediators differentially regulate megakaryopoiesis and thrombopoiesis in myelofibrosis and essential thrombocythemia

  2025influential citation
• A proteogenomic gene signature defines prognostic subgroups highlighting PI3K/AKT/mTOR signaling pathway as a therapeutic vulnerability in myeloid malignancies

  2025cites this paper
• Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives

  2025cites this paper
• Targeting CD38 effectively prevents myelofibrosis in myeloproliferative neoplasms

  2025cites this paper
• RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia

  2025cites this paper
• Neutrophils in BCR::ABL1 negative MPN: Contributors or bystanders of fibrosis?

  2025cites this paper
• Smoothened Inhibitor, PF-04449913 Inhibits the Development of Myelofibrosis in a JAK2V617F Transgenic Mouse Model by Reducing TGF-β and MAPK Signaling Pathways

  2025cites this paper
• Elevated levels of damage-associated molecular patterns HMGB1 and S100A8/A9 coupled with toll-like receptor-triggered monocyte activation are associated with inflammation in patients with myelofibrosis

  2024cites this paper
• Population dynamics modeling reveals that myeloid bias involves both HSC differentiation and progenitor proliferation biases

  2024cites this paper
• Pacritinib prevents inflammation-driven myelofibrosis-like phenotype in a miR-146a-/- murine model.

  2024cites this paper
• IDH2 mutation accelerates TPO‐induced myelofibrosis with enhanced S100a8/a9 and NFκB signaling in vivo

  2024cites this paper
• Single-cell mass cytometry in immunological skin diseases

  2024cites this paper
• miR‐146a−/− mice model reveals that NF‐κB inhibition reverts inflammation‐driven myelofibrosis‐like phenotype

  2024cites this paper
• Momelotinib in myelofibrosis

  2024cites this paper
• A phase I trial of pevonedistat in combination with ruxolitinib for the treatment of myelofibrosis

  2024cites this paper
• CXCL8 and its cognate receptors CXCR1/CXCR2 in primary myelofibrosis

  2024cites this paper
• Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasms

  2023influential citation
• Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms

  2023cites this paper
• High cell-free DNA is associated with disease progression, inflammasome activation and elevated levels of inflammasome-related cytokine IL-18 in patients with myelofibrosis

  2023cites this paper
• Single-cell omics techniques to elucidate cell-to-cell variability in signalling cascades involved in human diseases

  2023cites this paper
• Complementary and countervailing actions of Jak2 and Ikk2 in hematopoiesis in mice.

  2023cites this paper
• Mass Cytometry as a Tool for Investigating Senescence in Multiple Model Systems

  2023cites this paper
• Inflammation and bone marrow fibrosis: novel immunotherapeutic targets

  2023cites this paper
• Role of IL8 in myeloid malignancies

  2023cites this paper
• Identification of curaxin as a potential new therapeutic for JAK2 V617F mutant patients

  2023cites this paper
• Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study

  2023cites this paper
• PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in patients with Myelofibrosis.

  2023cites this paper
• The Role of NLRP3, a Star of Excellence in Myeloproliferative Neoplasms

  2023cites this paper
• In vivo ablation of NFκB cascade effectors alleviates disease burden in myeloproliferative neoplasms.

  2023cites this paper
• DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression

  2022cites this paper
• Biology and therapeutic targeting of molecular mechanisms in MPNs

  2022cites this paper
• Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression

  2022cites this paper
• miR-29b-3p suppresses the malignant biological behaviors of AML cells via inhibiting NF-κB and JAK/STAT signaling pathways by targeting HuR

  2022cites this paper
• Identification of potential pathways and microRNA-mRNA networks associated with benzene metabolite hydroquinone-induced hematotoxicity in human leukemia K562 cells

  2022cites this paper
• Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond.

  2022cites this paper
• Understanding Aberrant Signaling to Elude Therapy Escape Mechanisms in Myeloproliferative Neoplasms

  2022cites this paper
• Defining disease modification in myelofibrosis in the era of targeted therapy

  2022cites this paper
• Study of Tumor Necrosis Factor-Alpha-Induced Protein 3 Gene Single-Nucleotide Variants in JAK2 V617F-Positive Myeloproliferative Disorders: A Case–Control Study

  2022cites this paper
• Neutrophil Death in Myeloproliferative Neoplasms: Shedding More Light on Neutrophils as a Pathogenic Link to Chronic Inflammation

  2022cites this paper
• Proteomic identification of proliferation and progression markers in human polycythemia vera stem and progenitor cells

  2022influential citation
• Expression profiles analysis identifies specific interferon-stimulated signatures as potential diagnostic and predictive indicators of JAK2V617F + myelofibrosis

  2022cites this paper
• Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition

  2021influential citation
• Focus on Osteosclerotic Progression in Primary Myelofibrosis

  2021cites this paper
• Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B

  2021cites this paper
• High Throughput Multi-Omics Approaches for Clinical Trial Evaluation and Drug Discovery

  2021cites this paper
• Mass Cytometry, Imaging Mass Cytometry, and Multiplexed Ion Beam Imaging Use in a Clinical Setting.

  2021cites this paper
• Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms

  2021influential citation
• HuR targeted by miR-29b-3p suppresses the malignant biological behaviors of AML cells via the NF-κB and JAK/STAT signaling pathways

  2021cites this paper
• Early and late stage MPN patients show distinct gene expression profiles in CD34+ cells

  2021cites this paper
• Paradigm shift: combination BET and JAK inhibition in myelofibrosis

  2021cites this paper
• From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox

  2021cites this paper
• The Application of Single-Cell Technologies in Cardiovascular Research

  2021cites this paper
• Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis

  2021cites this paper
• Mass Cytometry in Hematologic Malignancies: Research Highlights and Potential Clinical Applications

  2021cites this paper
• CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis

  2021cites this paper
• DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression

  2021cites this paper
• Clinical Insights into the Origins of Thrombosis in Myeloproliferative Neoplasms.

  2020cites this paper
• A Humanized Animal Model Predicts Clonal Evolution and Therapeutic Vulnerabilities in Myeloproliferative Neoplasms

  2020cites this paper
• Synergic Crosstalk between Inflammation, Oxidative Stress, and Genomic Alterations in BCR–ABL-Negative Myeloproliferative Neoplasm

  2020cites this paper
• Progress and applications of mass cytometry in sketching immune landscapes

  2020cites this paper
• Genetic polymorphisms and expression of NLRP3 inflammasome-related genes are associated with Philadelphia chromosome-negative myeloproliferative neoplasms.

  2020cites this paper
• Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis

  2020cites this paper
• A proteomic study of myeloproliferative neoplasms using reverse-phase protein arrays

  2020cites this paper
• Evolution of clonal dynamics and differential response to targeted therapy in a case of systemic mastocytosis with associated myelodysplastic syndrome.

  2020cites this paper
• Role of inflammation in the biology of myeloproliferative neoplasms.

  2020cites this paper
• Platelet Toll-Like Receptors Mediate Thromboinflammatory Responses in Patients With Essential Thrombocythemia

  2020cites this paper
• Management of myelofibrosis after ruxolitinib failure

  2020cites this paper
• Myelofibrosis biology and contemporary management

  2020cites this paper
• The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells

  2020cites this paper
• Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models

  2019cites this paper
• Proteomic tools and new insights for the study of B-cell precursor acute lymphoblastic leukemia

  2019cites this paper
• HCV and flaviviruses hijack cellular mechanisms for nuclear STAT2 degradation: Up-regulation of PDLIM2 suppresses the innate immune response

  2019cites this paper
• Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms

  2019cites this paper
• Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling

  2019cites this paper
• Melatonin inhibits MLL-rearranged leukemia via RBFOX3/hTERT and NF-κB/COX-2 signaling pathways.

  2019cites this paper
• Bone marrow – speci fi c loss of ABI 1 induces myeloproliferative neoplasm with features resembling human myelo fi brosis

  2018cites this paper
• Fbxw11 promotes the proliferation of lymphocytic leukemia cells through the concomitant activation of NF-κB and β-catenin/TCF signaling pathways

  2018cites this paper
• JARID2 Functions as a Tumor Suppressor in Myeloid Neoplasms by Repressing Self-Renewal in Hematopoietic Progenitor Cells.

  2018cites this paper
• Bone marrow-specific loss of ABI1 induces myeloproliferative neoplasm with features resembling human myelofibrosis.

  2018cites this paper
• CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer

  2018cites this paper
• CHAPTER EIGHT Single‐Cell Proteomics for Cancer Immunotherapy

  2018cites this paper
• BET'ing on Dual JAK/BET Inhibition as a Therapeutic Strategy for Myeloproliferative Neoplasms.

  2018cites this paper
• Mass cytometry: a powerful tool for dissecting the immune landscape.

  2018cites this paper
• Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML

  2018cites this paper
• Identification of functionally primitive and immunophenotypically distinct subpopulations in secondary acute myeloid leukemia by mass cytometry

  2018cites this paper
• Advances in high-dimensional mass cytometry cell and tissue analyses for translational biomarker discovery

  2017cites this paper
• Novel single‐cell technologies in acute myeloid leukemia research

  2017cites this paper
• Applications of Mass Cytometry in Clinical Medicine: The Promise and Perils of Clinical CyTOF.

  2017cites this paper
• Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease.

  2017cites this paper
• Integrated functional and mass spectrometry-based flow cytometric phenotyping to describe the immune microenvironment in acute myeloid leukemia.

  2017cites this paper
• Defining Renal Neoplastic Disease, One Cell at a Time: Mass Cytometry, a New Tool for the Study of Kidney Biology and Disease.

  2017cites this paper
• Becker Digital Commons

  year unknowncites this paper
• Multiomic profiling reveals metabolic alterations mediating Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative aberrant platelet activity and inflammation in myeloproliferative neoplasms neoplasms

  year unknowncites this paper